- Home
- SLGN vs IONS Comparison
SLGN vs IONS Comparison
Compare SLGN & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGN
- IONS
- Stock Information
- Founded
- SLGN 1987
- IONS 1989
- Country
- SLGN United States
- IONS United States
- Employees
- SLGN N/A
- IONS N/A
- Industry
- SLGN Containers/Packaging
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- SLGN Industrials
- IONS Health Care
- Exchange
- SLGN Nasdaq
- IONS Nasdaq
- Market Cap
- SLGN N/A
- IONS 6.0B
- IPO Year
- SLGN 1997
- IONS 1991
- Fundamental
- Price
- SLGN $50.73
- IONS $30.97
- Analyst Decision
- SLGN Strong Buy
- IONS Buy
- Analyst Count
- SLGN 9
- IONS 18
- Target Price
- SLGN $64.22
- IONS $60.50
- AVG Volume (30 Days)
- SLGN 947.7K
- IONS 1.5M
- Earning Date
- SLGN 04-30-2025
- IONS 05-06-2025
- Dividend Yield
- SLGN 1.58%
- IONS N/A
- EPS Growth
- SLGN N/A
- IONS N/A
- EPS
- SLGN 2.58
- IONS N/A
- Revenue
- SLGN $5,854,694,000.00
- IONS $705,138,000.00
- Revenue This Year
- SLGN $11.91
- IONS N/A
- Revenue Next Year
- SLGN $2.58
- IONS $25.98
- P/E Ratio
- SLGN $19.61
- IONS N/A
- Revenue Growth
- SLGN N/A
- IONS N/A
- 52 Week Low
- SLGN $41.14
- IONS $30.23
- 52 Week High
- SLGN $58.14
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- SLGN 46.30
- IONS 42.33
- Support Level
- SLGN $49.29
- IONS $31.04
- Resistance Level
- SLGN $51.85
- IONS $33.76
- Average True Range (ATR)
- SLGN 1.07
- IONS 1.19
- MACD
- SLGN 0.19
- IONS -0.21
- Stochastic Oscillator
- SLGN 68.89
- IONS 8.92
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.